DNA-intercalators causing rapid re-expression of methylated and silenced genes in cancer cells

Oncotarget

Volumn 4, Issue 2, 2013, Pages 298-309

  Hossain, M Zulfiquer ^a   Healey, Megan A ^a   Lee, Calvin ^a   Poh, Weijie ^a   Yerram, Sashidhar R ^a   Patel, Kalpesh ^a   Azad, Nilofer S ^a   Herman, James G ^a   Kern, Scott E ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cancer; Demethylation; DNA intercalator; DNMT inhibitor; Epigenetics; Gene methylation; Quinacrine; Silencing and reactivation of gene expression; Small molecule DNA interactions

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; ACRIDIN 9 YL[4 (4 METHYLPIPERAZIN 1 YL)PHENYL]AMINE; ACRIDINE DERIVATIVE; DNA METHYLTRANSFERASE 1; ETOPOSIDE; FLUOROURACIL; MEPACRINE; MITOMYCIN; N4 BENZO[G]QUINOLIN 4 YL N1,N1 DIETHYLPENTANE 1,4 DIAMINE; PLACENTA PROTEIN 5; PROTEIN P16; QUERCETIN; SECRETED FRIZZLED RELATED PROTEIN 1; SECRETED FRIZZLED RELATED PROTEIN 5; TRICHOSTATIN A; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CDH13 GENE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; DOSE TIME EFFECT RELATION; DRUG MECHANISM; DRUG SPECIFICITY; DRUG STRUCTURE; E CADHERIN GENE; ENZYME INHIBITION; EPIGENETICS; GENE; GENE ACTIVATION; GENE EXPRESSION; GENE SILENCING; HISTONE ACETYLATION; IN VITRO STUDY; INTERCALATION COMPLEX; MOLECULAR DYNAMICS; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN LOCALIZATION; SECRETED FIZZLE RELATED PROTEIN 1 GENE; SECRETED FIZZLE RELATED PROTEIN 5 GENE; TFPI2 GENE; TUMOR SUPPRESSOR GENE;

EID: 84875777387     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.863     Document Type: Article

References (48)

1. Herman JG and Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003; 349(21):2042-2054.
2. Jenuwein T and Allis CD. Translating the histone code. Science. 2001; 293(5532):1074-1080.
3. Strahl BD and Allis CD. The language of covalent histone modifications. Nature. 2000; 403(6765):41-45.
4. Cohen DE and Melton D. Turning straw into gold: directing cell fate for regenerative medicine. Nat Rev Genet. 12(4):243-252.
5. Christman JK. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002; 21(35):5483-5495.
6. Cameron EE, Bachman KE, Myohanen S, Herman JG and Baylin SB. Synergy of demethylation and histonedeacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999; 21(1):103-107.
7. Cunningham SC, Ryu B, Sohn TA and Kern SE. Nonspecific enhancement of gene expression by compounds identified in high-throughput cell-based screening. Biotechniques. 2004; 37(1):120-122.
8. Sebestik J, Hlavacek J and Stibor I. A role of the 9-aminoacridines and their conjugates in a life science. Curr Protein Pept Sci. 2007; 8(5):471-483.
9. Su GH, Sohn TA, Ryu B and Kern SE. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res. 2000; 60(12):3137-3142.
10. Sakai M, Hibi K, Koshikawa K, Inoue S, Takeda S, Kaneko T and Nakao A. Frequent promoter methylation and gene silencing of CDH13 in pancreatic cancer. Cancer Sci. 2004; 95(7):588-591.
11. Winter JM, Ting AH, Vilardell F, Gallmeier E, Baylin SB, Hruban RH, Kern SE and Iacobuzio-Donahue CA. Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer. Clin Cancer Res. 2008; 14(2):412-418.
12. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte-Waldhoff I, Schmiegel W, Baylin SB, Kern SE and Herman JG. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 1997; 57(15):3126-3130.
13. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, Pretlow TP, Yang B, Akiyama Y, Van Engeland M, Toyota M, Tokino T, Hinoda Y, Imai K, Herman JG and Baylin SB. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet. 2004; 36(4):417-422.
14. Sato N, Parker AR, Fukushima N, Miyagi Y, Iacobuzio-Donahue CA, Eshleman JR and Goggins M. Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene. 2005; 24(5):850-858.
15. Schuebel KE, Chen W, Cope L, Glockner SC, Suzuki H, Yi JM, Chan TA, Van Neste L, Van Criekinge W, van den Bosch S, van Engeland M, Ting AH, Jair K, Yu W, Toyota M, Imai K, et al. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet. 2007; 3(9):1709-1723.
16. Ghoshal K, Datta J, Majumder S, Bai S, Kutay H, Motiwala T and Jacob ST. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol. 2005; 25(11):4727-4741.
17. Sallinen J, Hoglund I, Engstrom M, Lehtimaki J, Virtanen R, Sirvio J, Wurster S, Savola JM and Haapalinna A. Pharmacological characterization and CNS effects of a novel highly selective alpha2C-adrenoceptor antagonist JP-1302. Br J Pharmacol. 2007; 150(4):391-402.
18. Harle DG and Baldo BA. Structural features of potent inhibitors of rat kidney histamine N-methyltransferase. Biochem Pharmacol. 1988; 37(3):385-388.
19. Gallant JN, Allen JE, Smith CD, Dicker DT, Wang W, Dolloff NG, Navaraj A and El-Deiry WS. Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. Cancer Biol Ther. 12(3):239-251.
20. Wang W, Gallant JN, Katz SI, Dolloff NG, Smith CD, Abdulghani J, Allen JE, Dicker DT, Hong B, Navaraj A and El-Deiry WS. Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer Biol Ther. 12(3):229-238.
21. Lin J, Haffner MC, Zhang Y, Lee BH, Brennen WN, Britton J, Kachhap SK, Shim JS, Liu JO, Nelson WG, Yegnasubramanian S and Carducci MA. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth. Prostate. 71(4):333-343.
22. Mercurio C, Minucci S and Pelicci PG. Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol Res. 62(1):18-34.
23. Huang Y, Greene E, Murray Stewart T, Goodwin AC, Baylin SB, Woster PM and Casero RA, Jr. Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc Natl Acad Sci U S A. 2007; 104(19):8023-8028.
24. Liu F, Chen X, Allali-Hassani A, Quinn AM, Wasney GA, Dong A, Barsyte D, Kozieradzki I, Senisterra G, Chau I, Siarheyeva A, Kireev DB, Jadhav A, Herold JM, Frye SV, Arrowsmith CH, et al. Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a. J Med Chem. 2009; 52(24):7950-7953.
25. Huang HS, Allen JA, Mabb AM, King IF, Miriyala J, Taylor-Blake B, Sciaky N, Dutton JW, Lee HM, Chen X, Jin J, Bridges AS, Zylka MJ, Roth BL and Philpot BD. Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons. Nature.
26. Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, Welsh W and Yang CS. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 2003; 63(22):7563-7570.
27. Fang MZ, Chen D, Sun Y, Jin Z, Christman JK and Yang CS. Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy. Clin Cancer Res. 2005; 11(19 Pt 1):7033-7041.
28. Day JK, Bauer AM, DesBordes C, Zhuang Y, Kim BE, Newton LG, Nehra V, Forsee KM, MacDonald RS, Besch-Williford C, Huang TH and Lubahn DB. Genistein alters methylation patterns in mice. J Nutr. 2002; 132(8 Suppl):2419S-2423S.
29. Tan S, Wang C, Lu C, Zhao B, Cui Y, Shi X and Ma X. Quercetin is able to demethylate the p16INK4a gene promoter. Chemotherapy. 2009; 55(1):6-10.
30. Yuan B, Zhang J, Wang H, Xiong L, Cai Q, Wang T, Jacobsen S, Pradhan S and Wang Y. 6-Thioguanine reactivates epigenetically silenced genes in acute lymphoblastic leukemia cells by facilitating proteasomemediated degradation of DNMT1. Cancer Res. 71(5):1904-1911.
31. Parker BS, Cutts SM, Nudelman A, Rephaeli A, Phillips DR and Sukumar S. Mitoxantrone mediates demethylation and reexpression of cyclin d2, estrogen receptor and 14.3.3sigma in breast cancer cells. Cancer Biol Ther. 2003; 2(3):259-263.
32. Pina IC, Gautschi JT, Wang GY, Sanders ML, Schmitz FJ, France D, Cornell-Kennon S, Sambucetti LC, Remiszewski SW, Perez LB, Bair KW and Crews P. Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase. J Org Chem. 2003; 68(10):3866-3873.
33. Cornacchia E, Golbus J, Maybaum J, Strahler J, Hanash S and Richardson B. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J Immunol. 1988; 140(7):2197-2200.
34. Segura-Pacheco B, Trejo-Becerril C, Perez-Cardenas E, Taja-Chayeb L, Mariscal I, Chavez A, Acuna C, Salazar AM, Lizano M and Duenas-Gonzalez A. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin Cancer Res. 2003; 9(5):1596-1603.
35. Villar-Garea A, Fraga MF, Espada J and Esteller M. Procaine is a DNA-demethylating agent with growthinhibitory effects in human cancer cells. Cancer Res. 2003; 63(16):4984-4989.
36. Richardson B, Cornacchia E, Golbus J, Maybaum J, Strahler J and Hanash S. N-acetylprocainamide is a less potent inducer of T cell autoreactivity than procainamide. Arthritis Rheum. 1988; 31(8):995-999.
37. Fu HY, Shen JZ, Wu Y, Shen SF, Zhou HR and Fan LP. Arsenic trioxide inhibits DNA methyltransferase and restores expression of methylation-silenced CDKN2B/ CDKN2A genes in human hematologic malignant cells. Oncol Rep. 24(2):335-343.
38. Datta J, Ghoshal K, Denny WA, Gamage SA, Brooke DG, Phiasivongsa P, Redkar S and Jacob ST. A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. Cancer Res. 2009; 69(10):4277-4285.
39. Brueckner B, Garcia Boy R, Siedlecki P, Musch T, Kliem HC, Zielenkiewicz P, Suhai S, Wiessler M and Lyko F. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res. 2005; 65(14):6305-6311.
40. Amato RJ. Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy. Clin Genitourin Cancer. 2007; 5(7):422-426.
41. Davis AJ, Gelmon KA, Siu LL, Moore MJ, Britten CD, Mistry N, Klamut H, D'Aloisio S, MacLean M, Wainman N, Ayers D, Firby P, Besterman JM, Reid GK and Eisenhauer EA. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest New Drugs. 2003; 21(1):85-97.
42. Stewart DJ, Donehower RC, Eisenhauer EA, Wainman N, Shah AK, Bonfils C, MacLeod AR, Besterman JM and Reid GK. A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. Ann Oncol. 2003; 14(5):766-774.
43. Klisovic RB, Stock W, Cataland S, Klisovic MI, Liu S, Blum W, Green M, Odenike O, Godley L, Burgt JV, Van Laar E, Cullen M, Macleod AR, Besterman JM, Reid GK, Byrd JC, et al. A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clin Cancer Res. 2008; 14(8):2444-2449.
44. Winquist E, Knox J, Ayoub JP, Wood L, Wainman N, Reid GK, Pearce L, Shah A and Eisenhauer E. Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study. Invest New Drugs. 2006; 24(2):159-167.
45. Chuang JC, Yoo CB, Kwan JM, Li TW, Liang G, Yang AS and Jones PA. Comparison of biological effects of nonnucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine. Mol Cancer Ther. 2005; 4(10):1515-1520.
46. Stresemann C, Brueckner B, Musch T, Stopper H and Lyko F. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res. 2006; 66(5):2794-2800.
47. Fathi AT and Abdel-Wahab O. Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy. Adv Hematol. 2012:469-592.
48. Ahmed MS, Ramesh V, Nagaraja V, Parish JH and Hadi SM. Mode of binding of quercetin to DNA. Mutagenesis. 1994; 9(3):193-197.